
An expert in gastric cancers describes when and for whom molecular testing should be done in patients with metastatic HER2+ gastric cancer, and which tests are move relevant to treatment decision-making.

Your AI-Trained Oncology Knowledge Connection!


An expert in gastric cancers describes when and for whom molecular testing should be done in patients with metastatic HER2+ gastric cancer, and which tests are move relevant to treatment decision-making.

John Marshall, MD, reviews the case of a patient with metastatic HER2+ (human epidermal growth factor receptor 2) gastroesophageal junction cancer.

Jamile Shammo, MD, reviews initial treatment options for patients with low risk polycythemia vera.

Dr. Ruben Mesa and panel discuss the importance of and methods for risk assessment in patients with polycythemia vera.

Experts in MPN discuss diagnostic considerations for polycythemia vera.

Prithviraj Bose, MD, reviews the case of a 57-year-old man diagnosed with polycythemia vera.








Andrew G. Gianoukakis, MD, of Harbor-UCLA Medical Center, describes the rationale for treating a patient with RAI-refractory differentiated thyroid cancer with systemic therapy.